NCT Number: NCT00219661
Effect of Drainage of Subglottic Secretions on Pneumonia Acquired Under Mechanical Ventilation
The purpose of this study is to determine whether drainage of subglottic secretions is effective to reduce the incidence of pneumonia acquired under mechanical ventilation in ICU's patients.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Avignon Hospital, Avignon, France
About this study
Nosocomial infection represent a major problem in hospitals. In intensive care units, ventilator-associated pneumonia (VAP) is associated with an increase in morbidity and mortality. Incidence of VAP is high, 20 to 30% of patients under mechanical ventilation (MV) for more than 48 hours. In the pathogenesis of VAP, two processes are considered essential for its development: bacterial colonization of the oropharynx and tracheobronchial tract, followed by aspiration of contaminated secretions into the lower airways. It has been shown that pooled secretions above inflated endotracheal tube cuffs may be source of aspiration and can be a cause of VAP. Several studies have suggested that recurrent aspiration of subglottic secretions can be prevented by intermittent drainage of subglottic secretions. Nevertheless, recent CDC guideline reported that there was not enough evidence to conclude on the efficacy of such intervention.
During the study, patients, in both groups, will be intubated with the same device permitting subglottic drainage (HiLo Evac endotracheal tube). The daily screening of VAP will be performed until the 28th days of mechanical ventilation without occurrence of VAP. The follow-up of each patient will be realized until the ICU's discharge.
Comparison: The incidence of VAP will be compared between two groups: one group with intermittent drainage of subglottic secretions and the other one without this intervention.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- ICU patients expected to require MV more than 48 hours
Exclusion criteria
- patients already intubated for more than 12 hours
- patients intubated with another tube than the HiLo Evac tube
- patients admitted for cardiac arrest
- patients admitted for self poisoning
- patients admitted with tracheotomy
- patients already included in an another clinical trial
Treatment and study plan
Primary outcomes
-
Incidence of ventilator-associated pneumonia(VAP)
Secondary outcomes
-
Duration on mechanical ventilation (MV)
-
Prior duration of MV before occurrence of VAP
-
duration of ICU's stay
-
Rate of tracheotomy
-
ICU's mortality
-
Microbiology of the VAP
Sponsors and collaborators
Lead sponsor
Poissy-Saint Germain Hospital
Other
Registry information
Official study title
Impact of Drainage of Subglottic Secretions on Ventilator-Associated Pneumonia:a Randomised Multicentre Trial
Important dates
- Study start
- 2003
- Study completion
- 2006
- First posted
- Sep 22, 2005
- Registry last updated
- Apr 23, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Colistin Versus Colistin Combined With Cefoperazone-sulbactam for Multiresistant Acinetobactor Baumannii Ventilator-associated Pneumonia Treatment
NCT07671755
Clinical Response, Cross Infection
Karachi, Pakistan
View Trial DetailsOropharyngeal Care With Colostrum, Chlorohexidine and Sodium Bicarbonate in Preventing Ventilator-associated Pneumonia in Preterm Neonates
NCT07482007
Cross Infection, Disease Attributes
Tanta, Egypt
View Trial DetailsEfficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.
NCT04276480
Bacterial Infections, Bacterial Infections and Mycoses
Bayonne, France
View Trial DetailsDiagnostic and Prognostic Value of Reticulated Platelet Fraction in Ventilator-Associated Pneumonia (REPLAY-VAP)
NCT07013032
Cross Infection, Disease Attributes
Konya, Karatay, Turkey (Türkiye)
View Trial Details